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Abstract 18	
Monoclonal antibodies (mAbs) have come to dominate the biologics market in human 19	
cancer therapy. Nevertheless, in veterinary medicine very few clinical trials have been 20	
initiated using this form of therapy. Some of the advantages of monoclonal antibody 21	
therapeutics over conventional drugs are high specificity, precise mode of action and long 22	
half-life which favours infrequent dosing of the antibody. Further advancement in the field of 23	
biomedical sciences has led to the production of different forms of the antibody such as 24	
single chain antibody fragment (scFv), Fab, bi-specific and drug conjugates for use in 25	
diagnostic and therapeutic purposes. In this review we describe the potential for monoclonal 26	
antibodies in veterinary oncology patients in supporting both diagnosis and therapy of cancer. 27	
We explore the technical and financial hurdles to facilitate clinical acceptance of mAbs and 28	
offer insights into novel technologies and targets that could support more rapid clinical 29	
development.  30	
 31	
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 44	
Introduction 45	
The history of monoclonal antibody (mAb) therapy can be traced back to the start of 46	
the hybridoma technology, in 1975 (Köhler and Milstein, 1975). Fig. 1 describes the 47	
chronology of mAb development.  48	
 49	
The greatest advances in monoclonal antibody therapeutics began when recombinant 50	
DNA technology could be applied to antibody design. This facilitated the reduction in their 51	
immunogenicity and optimisation of antibody half-life and effector functions. Despite that, 52	
mAbs have taken a long time since the early days of discovery until the current “golden 53	
phase” of cancer therapies using biologicals (Waldmann, 1991). Since then, anti-cancer 54	
mAbs – and also mAbs for other therapeutic purposes – have become some of the highest 55	
selling medicines ever (King, 2013).  56	
 57	
The importance of monoclonal antibodies as therapeutics is increasing, and currently 58	
there is an average of four new molecules reaching the human therapeutics market every 59	
year. This class of treatment is seen as critical for the future of the pharmaceutical industry, 60	
especially in a time when the development of new drugs and the discovery of new targets is 61	
declining (Munro et al., 2011; Arrowsmith, 2012; Ecker et al., 2014). 62	
 63	
Mechanisms of action 64	
Several mechanisms of action of the monoclonal antibodies have been identified. 65	
They are summarised in Table 1 per the molecular mechanism to which they are relevant 66	
(Glennie and Johnson, 2000; Adams and Weiner, 2005).  67	
 68	
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Many antibody functions shown in Table 1 are dependent on the Fc region of the 69	
mAb. The interaction between the Fc region of the mAb and Fc receptors (FcR) is crucial for 70	
the development of immune-mediated functions of the antibody, such as antibody-dependent 71	
cell-mediated cytotoxicity (ADCC). Complement-dependent cytotoxicity (CDC) can also be 72	
activated by interaction with the Fc fraction of the mAb. This interaction is specific, such that 73	
not all antibody isotypes interact with the same intensity with the FcR, even within the IgG 74	
subclass in a single species, for instance (Bergeron et al., 2014; Strietzel et al., 2014). 75	
Therefore, the choice of Fc region during the chimerisation process (described below) affects 76	
the effector functions of the therapeutic speciated mAb. In dogs, IgGB and IgGC are capable 77	
of driving ADCC and CDC, while IgGD is only capable of activating the complement 78	
cascade (for CDC), but not of binding to FcγRs (for ADCC or phagocytosis). The other IgG 79	
isotypes of dogs, “A” and “D” are not drivers of antibody-mediated immune responses. 80	
Human IgG1 and mouse IgG2a also bind to canine FcγRI, and are potentially useful as 81	
therapeutics in dogs (Helfand et al., 1994; Bergeron et al., 2014). Indeed, mAb 231, a murine 82	
antibody previously used against canine lymphoma (described below in detail), is reported to 83	
show antibody-mediated cytotoxicity and complement activation in dogs (Rosales et al., 84	
1988). In cats, feline IgG1a and IgG1b bind to Fc receptors and also seem capable of 85	
mediating CDC, while IgG2 does not (Strietzel et al., 2014). 86	
 87	
IgE-Fc receptor binding is also being explored as a potential mechanism to treat 88	
cancer. There are two views on the use of IgE antibodies against cancer: 1) IgE seems to have 89	
a role in preventing cancer; 2) IgE can be used to target FcεR-expressing mast cell tumours. 90	
As for the first approach on the use of IgE, this isotype is more effective in inducing ADCC 91	
against cancer cells, as well as inducing stronger responses (Singer and Jensen-Jarolim, 92	
2014). The second approach takes advantage of the high expression of IgE-binding Fc 93	
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receptors (FcεR) on mast cell tumours; thus, IgE can be used as a platform for the delivery of 94	
therapies to these cells (Elders et al., 2014). 95	
 96	
Monoclonal antibody therapy strategies for cancer in veterinary medicine 97	
The past of mAb therapy in veterinary medicine: mAb 231  98	
One of the first clinical monoclonal antibody licenced for cancer treatment, 99	
denominated mAb231, was for use in canine lymphoma, although it was later discontinued. 100	
(Jeglum, 2009; USDA, 2016). Three years before the licencing of the first cancer-targeted 101	
monoclonal antibody in Germany (Panorex), and five years before the first monoclonal 102	
antibody was licenced by the FDA for the treatment of cancer in humans (Rituximab), a 103	
monoclonal antibody received approval in the US to treat lymphoma in dogs, called mAb 104	
231. The selection of the monoclonal antibody was carried out against tumour cells and the 105	
molecular target of this antibody was never unveiled. Immunoprecipitation using the antibody 106	
did not display any protein. The antibody was nevertheless able to bind to 73% of the 107	
formalin-fixed and paraffin-embedded lymphomas tested (Steplewski et al., 1987; Jeglum, 108	
2009). The antibody is of the IgG2aκ subclass, with a detailed study of its structure having 109	
already been performed (Harris et al., 1997). Its mechanisms of action were reported to be 110	
due to antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent 111	
cytotoxicity (CDC) (Rosales et al., 1988) and inhibition of tumour growth (Steplewski et al., 112	
1987).   113	
 114	
The antibody was to be administered to dogs in remission after two four weeks’ 115	
cycles of vincristine, cyclophosphamide, L-asparaginase and doxorubicin (modified VCAA) 116	
and a three-week rest. The total dose was 100mg/m2, to be divided into 5 sequential days and 117	
to be administered over two hours. If lymphoma recurred after the administration of the Mab 118	
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231, a new 4-weeks cycle of the modified VCAA was to be administered, followed by a 3 119	
weeks’ rest and a new round of antibodies (Jeglum, 1996, 2009).  120	
 121	
The complete remission of the 215 dogs tested was 80.9%, with a mean survival time 122	
of 624.28 days for the responders (in complete remission) against 153.67 days for the non-123	
responders. Non-responders tended to be from the group of animals to which mAb231 does 124	
not bind on immunohistochemistry (Jeglum, 1996). Anecdotally, the administration of mAb 125	
231 showed a disproportional rate of achieving indefinite remission when compared to 126	
chemotherapeutics alone (Crow, 2008).  127	
 128	
The drug was discontinued in 1996, apparently due to lack of demand (Crow, 2008; 129	
Kaplan, 2008). This mAb is no longer licenced for use by the USDA (USDA, 2016). Yet, it 130	
must be brought to attention that the drug was marketed in a time when antibody therapy to 131	
cancer was non-existent in human medicine, nor had the subject the same attention it receives 132	
currently (Reichert, 2012).  133	
 134	
The present of mAb therapy in veterinary medicine: antibodies reaching the market 135	
The veterinary market is currently going through its first intense wave of interest in 136	
monoclonal antibodies (Harvey, 2015; Ledford, 2016). Two product launches by Aratana 137	
Therapeutics, against B (product AT-004, anti-CD20) and T cell lymphomas (AT-005, anti-138	
CD52) were widely regarded in the market as great promises for veterinary oncology. AT-139	
004 was shown to increase median progression-free survival of dogs with B cell lymphoma 140	
(Anderson and Modiano, 2015). However, recent post-USDA licencing trials have not shown 141	
encouraging results; in randomized clinical trials combining AT-005 to two different 142	
chemotherapy protocols, mAb therapy did not seem to improve clinical outcomes compared 143	
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to placebo. Aratana indicated that both AT-004 and AT-005 showed poor specificity to their 144	
respective targets. Despite this, both antibodies are currently still commercially available1. 145	
 146	
While other commercially available options of mAbs for the treatment of cancer in 147	
animals are not yet available, there are candidates approaching or at market launch for other 148	
clinical conditions. Zoetis has recently been granted a conditional licence by the USDA for 149	
lokivetmab, to be used for treatment of canine atopic dermatitis. This mAb blocks IL-31, 150	
which is important for the development of pruritus (Michels et al., 2016), with the intent of 151	
interrupting the cycle of itching and inflammation typical of atopic dermatitis (Zoetis, 2015)2. 152	
Nexvet Biopharma is investigating a target for chronic pain, with an anti-nerve growth factor 153	
mAb. Interestingly, they have already demonstrated the efficacy of this mAb both in 154	
caninised and in felinised formats (Gearing et al., 2013, 2016)3. 155	
 156	
The future of mAb therapy in veterinary medicine I: possible targets 157	
There is a limited number of publications evaluating the effects of monoclonal 158	
antibodies or related molecules in veterinary species. Shown below in Table 2 are antibodies 159	
that have been trialled or used in domestic animals, as well as future potential targets for 160	
these patients. 161	
 162	
The future of mAb therapy in veterinary medicine II: ‘speciation’ 163	
Veterinary medicine has always borrowed tools from human practice. However, 164	
contrarily to chemical drugs, biologicals such as mAbs are in most cases species-specific. 165	
																																								 																				
1 See: http://aratana.investorroom.com/2015-09-24-Aratana-Therapeutics-Provides-Product-Updates (accessed 
15 June 2016). 
2 See: http://news.zoetis.com/press-release/companion-animals/zoetis-receives-conditional-license-usda-canine-
atopic-dermatitis-im (acessed 16 June 2016) 
3 See: http://ir.nexvet.com/phoenix.zhtml?c=253841&p=irol-newsArticle&ID=2176442 (accessed 16 June 
2016).	
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Although the process of antibody caninisation is now becoming more widely used, it is still a 166	
time-consuming method (Gearing et al., 2013). Also, producing mAbs exclusively for one 167	
animal species may not be always commercially viable, and may impede further 168	
developments of new candidates. This is clearly illustrated by the fact that while there are 169	
now tens of monoclonal antibodies approved worldwide for cancer therapy in humans 170	
(Modjtahedi et al., 2012; Reichert, 2012; Ecker et al., 2015), in veterinary oncology, 171	
however, therapeutic antibodies are only just reaching the market (USDA, 2016).  172	
 173	
The use of antibodies that have been developed for human therapy in animals is an 174	
attractive approach. Some groups have explored the potential use of human mAbs in dogs. 175	
Stein and colleagues, for instance, successfully tested an anti-human leukocyte antigen DR in 176	
dogs. While it was then concluded that dogs were validated as good models for the trial of an 177	
antibody, the authors also note how the study and the patients would have benefited from a 178	
species-specific antibody (Impellizeri et al., 2006; Stein et al., 2011; Biller et al., 2014). 179	
 180	
Monoclonal antibody 231, the best example of mAb therapies in veterinary medicine, 181	
may have had reduced efficacy due to its xenogeneic origin. The canine anti-mouse antibody 182	
(CAMA) levels were raised after therapy with this antibody, and, as expected, further 183	
applications resulted in quicker and higher production of CAMA. No clinical disease seemed 184	
to arise from the use of this murine antibody in dogs. The investigators believed that length of 185	
remissions and survival times were not affected by the murine nature of the antibodies, but it 186	
was never directly compared to a ‘caninised’ version of the antibody (Jeglum, 1996, 2009). 187	
Possible side effects were occasionally observed, including facial oedema, erythema, fever, 188	
pruritus, vomiting and/or diarrhoea, joint pain and myalgia. Although the antibody seemed to 189	
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provide clinical benefits, it is possible that its murine origin was part of the reasons why it 190	
was later discontinued (Jeglum, 1996, 2009).  191	
 192	
Much more likely to be successful is the interchange of therapeutic antibodies 193	
between dogs and cats, for instance. Fc receptors, which are crucial for antibody half-life and 194	
effector functions, are very similar between these two domestic species (tested using Ensembl 195	
Genome Browser and ClustalOmega4) (Lobo et al., 2004; Strietzel et al., 2014). This could 196	
prove to be an important feature for veterinary practitioners when new mAbs become 197	
available for either species, since development of mAbs for these patients is slow and 198	
receives relatively little attention, especially for cats, for whom no mAb is available currently 199	
in the market.  200	
 201	
 Even though the majority of the literature indicates that anti-globulin responses limit 202	
the function of mAbs, as discussed above, there are still licensed antibodies for use in humans 203	
that are not humanised. Understanding how they are effective may set new parameters that 204	
may be useful for the production of innovative antibodies for domestic animals. 205	
 206	
 At least two mouse antibodies are still currently in use for the treatment of 207	
malignancies in humans. Both of these target CD20, and both are conjugated to 208	
radionuclides. The use of murine antibodies in humans is permitted in these cases because the 209	
mAbs are clinically useful with single dose schemes. Rituximab, a chimeric mAb that also 210	
targets CD20 in humans, is used in a course of several doses, in comparison (Witzig et al., 211	
2002; Burdick and Macklis, 2009). Further possible explanations for the low seroconversion 212	
from the use of these antibodies include the occurrence of immune suppression. It is expected 213	
																																								 																				
4	See:	http://www.ensembl.org/index.html	and	http://www.ebi.ac.uk/Tools/msa/clustalo/	(accessed	6	March	
2015).	
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that both normal and malignant B cells are depleted by the treatment, therefore limiting the 214	
capacity of the host to react to the mAbs (Mirick et al., 2004). Therefore, these results leave 215	
open the possibility of using non-speciated mAbs in animals if these are administered in 216	
single-dose regimens; mAbs coupled to radionuclides are potential candidates.  217	
 218	
The process of speciation 219	
As should be expected, xenogeneic antibodies are more immunogenic than syngeneic 220	
ones. Therefore, speciation was probably the single most important step towards the success 221	
of mAbs in clinical practice, since anti-mAb responses are responsible for rapid clearance of 222	
circulating mAbs as well as for several side effects (Glennie and Johnson, 2000). 223	
Chimerisation was the first stage towards antibody speciation (Hwang and Foote, 2005). In 224	
this technique, after the antibody is raised and selected from mouse hybridomas, the murine 225	
variable regions are cloned with human (or from any other species of interest) constant 226	
regions by fusing the immunoglobulin genes in an expression vector (Fig. 2). This is then 227	
expressed in a host system, such as Chinese hamster ovary (CHO) cells (Köhler and Milstein, 228	
1975; Persic et al., 1997).  229	
 230	
Humanisation is a further step in the engineering of the antibodies. This technology 231	
starts from the chimerised version of the mAb, and attempts to further reduce the 232	
immunogenicity of the antibody. In speciation, the framework regions of the variable fraction 233	
(the parts of the variable fraction which do not contact the antigen) of murine antibodies are 234	
substituted with human germline sequences. In this approach of speciation, CDRs are 235	
retained from the original murine mAb sequence.  236	
 237	
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To completely avoid murine sequences, additional strategies have been developed to 238	
generate fully speciated monoclonal antibodies through display technologies (such as phage 239	
display) and transgenic mice (Deckert, 2009; Bradbury et al., 2011). In fully human 240	
antibodies, all of the mAb molecule, including the CDRs, which bind to the antigen, are from 241	
the species of interest (Thie et al., 2008). Phage display relies on libraries of antibody 242	
fragments or whole IgGs (reviewed by Miersch & Sidhu, 2012) (Fig. 3). These can be 243	
constructed from samples of the species of interest; thus, a display library can contain the 244	
virtually the entirety of the antibodies being expressed in a blood sample, or a spleen, for 245	
instance. The ultimate aim of the display technology is the selection of the recombinant 246	
antibody that can bind to the antigen with highest affinity from the immense number of non-247	
specific antibodies in the library. After the construction of a display library putatively 248	
containing all the possible antibodies from one animal – or from several animals, if desired – 249	
this library can be screened against different therapeutic targets by the process of biopanning 250	
(Barbas et al., 1991). Since the library can be constructed from the target species, instead of 251	
mice, the antibodies it generates will be fully human (or canine, for example). Mice modified 252	
to contain a ‘human’ immune system are also used as an alternative for the production of 253	
fully human mAbs, but such a technology is not available for production of antibodies for 254	
domestic animals (Shultz et al., 2012). The aforementioned technologies associated with 255	
antibody production are illustrated in Fig. 4. 256	
 257	
Although full speciation of antibodies has become the industry standard (Modjtahedi 258	
et al., 2012), more recently opinions have emerged questioning the real benefits of 259	
engineering antibodies beyond chimerisation. As stated previously, chimerisation is 260	
responsible for the main reduction of immunogenicity of the mAbs. Indeed, in many cases 261	
chimerisation is enough to prevent anti-mAb formation. Full speciation also has the 262	
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disadvantages that it is a lengthy and labour-intensive laboratory process, delaying product 263	
launch, and in many cases leads to lower antibody affinity, since it interferes with the 264	
antibody variable regions (Kettleborough et al., 1991). New speciation techniques have been 265	
developed to try and circumvent these problems; one such example is the “PETization 266	
platform”, developed by a veterinary company (Gearing et al., 2013). However, full 267	
speciation does not guarantee that a mAb will not raise a host response, as has been seen with 268	
some fully humanised mAbs (Clark, 2000; Singh et al., 2012; van Meer et al., 2013; 269	
Waldmann, 2014).  270	
 271	
In veterinary medicine, the first speciated mAbs are now attaining the necessary legal 272	
approvals and are entering the market (Acharya et al., 2015), and it will be interesting to 273	
analyse the responses of large cohorts of animals to such caninised antibodies, in special with 274	
regards to side effects. 275	
 276	
Potential side effects of mAb therapy 277	
The side-effects of mAb therapy can arise as a consequence of a host reaction against 278	
the antibody or of the direct activity of the mAb. The host reactions against mAbs can be 279	
either acute (infusion reactions or anaphilactoid) or dependent on the formation of anti-mAbs. 280	
Acute reactions include the cytokine release syndrome (CRS) and systemic inflammatory 281	
response syndrome (SIRS). A number of counter-measures are recommended, such as 282	
hydration, premedication and gradual increase in the rate of infusion. Anaphylactic and 283	
‘anaphylactoid’ reactions occur more frequently with some antibodies than with others, 284	
probably due to the generation of IgE by the host. Adverse reactions can also be derived from 285	
the formation of anti-mAb antibodies after administration. These tend to appear and increase 286	
with subsequent doses, when the immune response has matured to secondary and adaptive 287	
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reactions. In these cases, high titres of anti-mAb IgGs can be found in the circulation of the 288	
patient. Monitoring anti-mAb responses relies on specialized techniques, not commonly 289	
available to the veterinary clinician; it depends on the concomitant development of the mAb 290	
with its coupled monitoring tests. Anti-mAb responses can be monitored, among other 291	
possibilities, by specific enzyme-linked immune sorbent assays (ELISAs), such as anti-292	
idiotype ELISA (for an explanation on anti-idiotypes, see Fig. 5 below and associated 293	
discussion) or antigen capture methods (Shankar et al., 2007; Renaudineau et al., 2009). 294	
 295	
Anti-mAb reactions may cause CRS and influenza-like symptoms in humans 296	
(McLaughlin et al., 1998; Hansel et al., 2010). In dogs, the murine mAb 231 caused clinical 297	
signs such as oedema and fever, but the occurrence of these signs did not impede subsequent 298	
administration of the treatment; however, the dogs were preventively treated with 299	
antihistamine, corticosteroids and the rate of infusion was reduced (Jeglum, 1996). It must be 300	
noted that side effect management and mAb treatment withdrawal should be considered on a 301	
case-by-case basis (Melosky et al., 2009). These host reactions tend to be more frequent 302	
when non-speciated (humanised or caninised) formulations are used, demonstrating the 303	
relevance of speciation (Adams and Weiner, 2005). The speciation process of antibodies, 304	
from chimerisation to full speciation, followed by fully human (or canine, feline) mAbs, 305	
reduces but does not exclude the probability of formation of strong host adverse reactions 306	
against the antibody. Moderate and mild host reactions may continue to occur, nonetheless 307	
(Hwang and Foote, 2005).  308	
 309	
Reactions against fully speciated mAbs (canine against canine antibodies, for 310	
instance) occur due to the inherent variability of antibodies. The antigen-binding region 311	
(named the complementarity-determining region, or CDR) is by definition always structurally 312	
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novel to the immune system itself – that means that antibodies are always immunogenic, 313	
regardless of how speciated the constant region of the mAb is. Although it is possible to 314	
change a few (1-2) amino acids in the CDR of a mAb to reduce its immunogenicity, these 315	
alterations always risk reducing the functionality of the antibody, since its very binding 316	
region is being altered (Harding et al., 2010). The immunogenic property of the CDRs create 317	
the phenomenon of the idiotype cascade presented in Fig. 5 (Herlyn et al., 1986). The main 318	
importance of full speciation seems to be to reduce “marked” anti-antibody responses. When 319	
reactions do occur against speciated mAbs, these tend to be “tolerable” or “negligible” 320	
(Hwang and Foote, 2005). 321	
 322	
The most common signs that follow the rapid infusion of rituximab, a human chimeric 323	
antibody, are vomiting and nausea, rash and hypotension. The prophylactic use of 324	
antipyretics and antihistamines is widespread to prevent these effects (Lang et al., 2011). 325	
However, major acute reactions such as CRS can occur. Similar effects are also known to 326	
occur after the administration of other chimeric mAbs such as Cetuximab (an anti-EGFR 327	
mAb). These strong adverse reactions are less common for fully human mAbs, such as 328	
Panitumumab (also anti-EGFR), but signs, such as skin rashes, still occur widely with the use 329	
of this antibody (Hansel et al., 2010). Nevertheless, it has been highlighted that the most 330	
common biological consequence of anti-mAb responses tends to be loss of efficacy, which is 331	
deleterious but not a safety concern (Shankar et al., 2007). 332	
 333	
 The second type of possible reactions is dependent on antibody activity. One possible 334	
effect of mAbs is the formation of Tumour Lysis Syndrome (TLS), where the release of 335	
intracellular contents from the tumour after being targeted by treatment leads to metabolic 336	
disorders, such as hyperkalaemia, hyperphosphatemia and hypocalcaemia (Jeha, 2001; 337	
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Gilbert and Wright, 2015). Undesired antibody activity has led to life threatening situations in 338	
the famous case of the CD28 superagonist antibody TGN1412, used with the goal of 339	
stimulating immune responses. This mAb had been trialled in human cells in vitro, in mice 340	
and in primates before reaching a human phase I clinical trial. However, in humans the mAb 341	
induced a severe cytokine storm (CRS): within minutes of administration patients had 342	
headaches, nausea, vomiting, pyrexia, a systemic inflammatory response with hypotension. 343	
This was followed by severe respiratory deterioration and several other signs of metabolic 344	
failure. It was later found that these effects were not predicted by pre-clinical tests due to 345	
immune differences between primates and mice compared humans – CD4 from macaques 346	
lose CD28 expression at the effector memory level, while mice induce strong regulatory T 347	
lymphocyte responses when administered with the superagonist. Additionally, the mere detail 348	
of cell density in cell culture assays seems to have affected the results so that the cytokine 349	
storm was also not predicted from these tests (Suntharalingam et al., 2006; Hünig, 2012).  350	
 351	
Other side-effects related to antibody function may derive from off-targets. None of 352	
the currently approved anti-cancer mAbs target a tumour-specific molecule. The targets are 353	
also expressed in normal tissues, albeit often at different concentrations. Adverse reactions 354	
therefore may originate from the off-targeting of the mAbs to molecules associated with 355	
physiological functions, but these events are rarely life threatening or debilitating 356	
(Modjtahedi et al., 2012).  357	
 358	
 When an antibody is used to block the function of leukocytic cancers, the possibility 359	
of side effects related to suppression of normal immune cells exists. Alemtuzumab, used for 360	
lymphoid malignancies, targets CD52, which also exists on the surface of normal circulating 361	
lymphocytes, leading to lymphocytopoenia for up to one year after treatment is discontinued. 362	
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One of the possible consequences is the appearance of opportunistic infections. Rituximab 363	
targets CD20 on the surface of B cells, but secondary infection is normally only a problem in 364	
patients that were already immunosuppressed or taking immunosuppressive drugs 365	
concomitantly. Nevertheless, transient decline in leukocytes can occur after use of Rituximab 366	
and caution is recommended when administering multiple courses of the antibody. 367	
Additionally, reactivation of latent hepatitis B infections has been recorded in patients 368	
receiving Rituximab (Sharma et al., 2007; Kelesidis et al., 2011; Uettwiller et al., 2011). 369	
 370	
Benefits of immunosuppression 371	
 Several factors influence the formation of anti-antibody responses by the patient 372	
receiving a mAb, such as the number of injections of the antibody, its immunogenicity and 373	
the immunocompetence of the recipient (Kuus-Reichel et al., 1994).  Reducing the immune 374	
response against the mAb is therefore an intuitive procedure that could make possible the use 375	
of extraneous antibodies or reduce the responses against antibodies. Indeed, it is believed that 376	
the lack of a negative reaction to some antibodies is due to the immunosuppressed status of 377	
the patients, either by the use of chemotherapy or because of the cancer activity itself 378	
(Glennie and Johnson, 2000). Suppression of human anti-mouse (HAMA) responses has been 379	
attempted with the administration of cyclosporine and other compounds. The use of 380	
cyclosporine was able to reduce the formation of anti-mAb responses and increase the 381	
amount of useful doses of mAbs that could be administered, but could not completely 382	
suppress HAMA in all the individuals tested or for an indefinite amount of administered 383	
doses (Ledermann et al., 1988; Weiden et al., 1994; Dhingra et al., 1995). CTLA-4 inhibits T 384	
lymphocyte activation by affecting the CD28-B7 co-stimulatory signal. Healthy beagle dogs 385	
simultaneously receiving an antibody fraction and the recombinant human CTLA-4 had 386	
better antibody responses. While dogs treated with the CTLA-4 had no side-effects after 5 387	
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doses of human antibody fractions, dogs that did not receive CTLA-4 simultaneously with the 388	
antibody showed hypersensitivity responses after 4 doses (pale mucous membranes, tremors, 389	
nasal discharge, and other signs). Also, the treatment seemed to reduce anti-antibody 390	
formation, allowing antibody plasma levels to be higher for longer periods (Siegall et al., 391	
1997). However, another study could not reproduce these results. The addition of CTLA-4 392	
did not inhibit the formation of anti- antibodies in this second study (Henry et al., 2005). 393	
 394	
Hurdles and opportunities 395	
The hurdles and opportunities in the study and production of new antibodies for 396	
veterinary use are discussed below and are summarised in Table 3. 397	
 398	
The immunogenicity of therapeutic molecules, including monoclonal antibodies, 399	
affects the efficacy and safety of the product (Chirino et al., 2004). For the veterinary field 400	
this still represents the greatest barrier for mAb usage in the clinical setting, although much 401	
still needs to be studied about the possible use of non-speciated mAbs. Clinical use of 402	
antibodies will benefit from the production of species-specific molecules (Gearing et al., 403	
2013). 404	
 405	
Cost represents an important concern for monoclonal therapies in humans. In 406	
veterinary medicine, this issue is even more relevant. The need for high cumulative doses and 407	
the fact that cancer is a chronic disease add to the fact that current methods for antibody 408	
production in mammalian cells are intrinsically expensive. Novel technologies such as 409	
transgenic animals and use of yeast, bacteria and insect culture systems are probable paths to 410	
be followed in the future for the production of antibodies (Daniell et al., 2001; Farid, 2007). 411	
This highlights the importance of better understanding the possibilities of using single-dose 412	
18 
	
non-speciated mAbs, which are substantially cheaper to produce, since the price of 413	
production will likely hinder the market accessibility of the veterinary biologics industry.  414	
 415	
Another limiting factor is the ability of the antibody to penetrate into the tumour. This 416	
accounts for one of the reasons why many mAbs that are promising during the developmental 417	
stage are not so successful clinically. Clearance from circulation, blood vessel density, 418	
vascular permeability and binding site barrier are some of the factors that influence mAb 419	
delivery (Lobo et al., 2004; Niu et al., 2009). Solutions include the use of antibody fragments 420	
such as scFv or Fab which exhibit better pharmacokinetics for penetration into the cancerous 421	
tissue and also possess high binding specificity (Batra et al., 2002). Direct intratumoural 422	
antibody administration and the administration of microencapsulated whole antibody-423	
producing cells or other in situ antibody producing technologies are possible means to 424	
circumvent these difficulties (Pelegrin et al., 1998; Azemar et al., 2003; Orive et al., 2003). 425	
Imaging techniques such as positron emission tomography (PET) offer high sensitivity which 426	
is required to monitor distribution of the drug throughout the body, to study pharmacokinetics 427	
and pharmacodynamics and also provide the information on optimal timing and antibody 428	
dosage (Rudin et al., 2005). These techniques will be central in the establishment of better 429	
mAb tumour penetration. 430	
 431	
Reduced efficiency of monoclonal antibodies during human clinical trials when 432	
compared to mouse trials is of major concern (Stein, 1997), and this might also be an issue 433	
when mAbs are to be used in veterinary medicine. Dogs represent a good model to study 434	
cancer on in respect to possible future applications in human patients. The genetic diversity 435	
of dogs is comparable to that of humans, and is larger than that of most rodent models; their 436	
cancer-associated genes show great similarities; cancers are naturally occurring, and appear 437	
19 
	
in animals with intact immune systems; similar factors influence the appearance of cancer in 438	
dogs and humans, such as age and environmental exposure to carcinogens. Indeed, clinical 439	
studies in dogs have shown that they serve as good predictors of both clinical toxicity and 440	
response to therapy (Paoloni and Khanna, 2008; London et al., 2009; Richards and Suter, 441	
2015). It would be in the interests of both veterinary medicine and of human medicine that 442	
dogs became an established intermediate in the studies of monoclonal antibodies. 443	
Experiments using human or murine mAbs in animals need to consider the potential benefits 444	
of the idiotype responses and the possibility of using mAbs in short dosing protocols. Quick 445	
chimerisation of antibodies and the study of cheaper expression systems would facilitate this 446	
process. It is very likely that once an antibody is fully arranged to be tested in dogs, the 447	
relevance of the results for human clinical trials would be improved when compared to mouse 448	
studies. 449	
 450	
Conclusions  451	
The current trend of biological therapeutics is now reaching veterinary medicine. 452	
While there are still many challenges to overcome in order to achieve commercial viability 453	
and wide accessibility of monoclonal antibodies for animal use, there are many opportunities 454	
in this field, as can be seen by the renewed interest of many research laboratories and private 455	
companies. Testing and using monoclonals clinically in veterinary medicine will be of benefit 456	
for both the animal patients and the development and improvement of human therapeutics. 457	
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Table 1 887	
Molecular mechanisms of action of monoclonal antibodies in cancer. 888	
 889	
Classes Mechanisms Mediators mAbs Effects 
Direct effects 
Blockade of 
signalling 
Neutralisation of 
mediators, cytokines, 
blockade of receptors, 
induction of apoptosis 
Apoptosis mediators 
Daclizumab 
Trastuzumab (other 
mechanisms also 
involved) 
Cetuximab 
Panitumumab 
Nivolumab 
Ipilimumab 
[nearly all 
commercially 
available antibodies 
for cancer affect 
signalling to some 
extent] 
Inhibition of 
proliferation and 
apoptosis 
Induction of 
signalling 
Protein tyrosine 
phosphorylation, 
upregulation of Myc 
p38 Map kinase,  
protein kinase C, 
Myc 
Rituximab 
Regulation of cell 
growth 
Conjugated 
antibodies 
Induction of cell death and 
inhibition of proliferation 
Drugs, toxin 
fragments, 
radioisotopes 
Tositumomab 
Ibritumomab 
tiuxetan 
Direct cell death 
Immune Mediated Effects 
ADCCa 
Interaction of mAb with 
FcγR bearing cells (NK, 
macrophages, neutrophils) 
with mAbs of IgG2a and 
IgG3 (in dogs receiving 
mouse mAb) or IgG1 and 
IgG3 (in humans)* 
[NK cells] IFNγ, 
cytotoxic granules 
(perforin, granulysin, 
granzymes), 
[Macrophages] ROS, 
proteases 
Rituximab 
Trastuzumab (other 
mechanisms also 
involved) 
Alemtuzumab 
Inhibition of cell 
proliferation, anti-
angiogenesis, cell 
lysis. The antigen 
presentation 
following cell death 
may induce a host 
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response. 
CDC 
Classical activation of 
complement system 
IgG1 and IgG3 Fc 
region (in humans)b; 
IgG2 region (in 
mice) and 
complement cascade 
(initiating with C1q) 
Alemtuzumab 
Rituximab 
Lysis of cells by the 
complement through 
the creation of pore 
on cell membrane. 
Enhancement of 
ADCC. 
Immunomodulation 
Checkpoint 
inhibitors 
Blockade of immune 
inhibitory receptors; 
approximation of immune 
cells to its target 
(trifunctional antibodies); 
activation of cells and 
induction of immune 
memory 
CTLA-4, PD-1, 
CD40, CD3, Fcγ 
receptors (mouse 
IgG2a and rat IgG2b 
in combination, for 
humans)c 
Catumaxomab; 
Ipilimumab 
Induction of T 
mediated lysis, 
ADCC, phagocytosis; 
reduction of tumour-
induced immune 
anergy 
 890	
aADCC, antibody-dependent cell-mediated cytotoxicity; CDC, complement-dependent 891	
cytotoxicity; IFN, interferon; FcγR, Fc gamma receptor; ROS, reactive oxygen species; NK, 892	
natural killer cells. 893	
bShuffled (engineered) isotypes of IgG1 and IgG3 in humans show a strong enhancement in 894	
the ADCC and CDC capacity (Kubota et al., 2009)  895	
cShuffled isotypes of mouse IgG2a and rat IgG2b show increased activation of human FcγR.  896	
References: (Rosales et al., 1988; Helfand et al., 1994; Pedersen et al., 2002; Iannello and 897	
Ahmad, 2005; Seimetz et al., 2010; Eissler et al., 2012; Golay and Introna, 2012; Anderson 898	
and Modiano, 2015) . 899	
 900	
 901	
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 904	
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 906	
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 908	
Table 2 909	
Potential targets in domestic animal species for monoclonal antibodies in oncology.  910	
 911	
Target (name 
of mAb) 
Condition 
targeted 
Potential to be used in animals Outcome in dogs (cats) Hurdles References 
CD20 B-cell lymphoma 
Dog PBMC stained with 
Rituximab. CD20 occurs in 
canine B-cell lymphomas. New 
antibodies developed for dogs 
(AT-004, 6C8, 1E4) 
mAb 6C8 had specific binding to 
canine B-cells 
mAb 1E4 (Elanco) has 
‘rituximab-like’ properties and 
depletes B-cells; chimeric version 
maintains function 
Rituximab does not 
bind peripheral blood 
dog cells. mAbs AT-
004 reached the market 
[Aratana/Novartis], 
with poor outcomes. 
 
Difference in aaa 
where Rituximab 
binds. 
Low affinity of 
AT-004 for its 
target 
(Jubala et al., 2005; 
Binder et al., 2006; 
Impellizeri et al., 
2006; Acharya et 
al., 2015; Aratana 
Therapeutics Inc, 
2015; Ito et al., 
2015; Rue et al., 
2015) 
CD52 T-cell lymphoma 
mAb received USDA approval 
for therapeutic use in dogs (AT-
005) 
Canine mAbs reached 
the market, but with 
poor responses 
[Aratana] 
Low affinity of the 
antibody for its 
target 
(Acharya et al., 
2015; Aratana 
Therapeutics Inc, 
2015) 
CD47 B-cell lymphoma 
Innate anti-tumor immune 
response such as phagocytosis 
increased against canine 
lymphoma by anti-CD47 mAb 
mAb treatment 
increased canine 
lymphoma phagocytosis 
in vitro 
None described 
(Anderson and 
Modiano, 
2015)(Anderson et 
al., 2016) 
α4β1 receptor 
(LLP2A) 
NHL 
Biodistribution of  LLP2A 
studied in dog as model for 
human 
Tumour affected tissues 
strongly targeted 
(preferentially B cells) 
None described 
(A L Zwingenberger 
et al., 2012; Allison 
L Zwingenberger et 
al., 2012) 
Lymphoma 
[target not 
defined] (mAb 
231) 
Lymphoma 
FDA approved for dog 
lymphoma. Binds 73% of tested 
lymphomas 
Increased complete 
remission in dogs 
combined with VCAA* 
Discontinued due 
to lack of demand. 
No longer USDA 
licensed 
(Steplewski et al., 
1987; Jeglum, 1996, 
2009; USDA, 2016) 
VEGF 
(Bevacizumab) 
Various cancers 
VEGF correlation with outcome 
ambiguous in dogs and cats. 
Molecular structure of VEGF/R 
similar between dog and man. 
Bavacizumab inhibited canine 
osteosarcoma and 
Delayed tumour growth 
and blood vessel 
formation in mice 
grafted with canine 
osteosarcoma 
Humanized mAb 
and cost of therapy 
(Scheidegger et al., 
1999; Millanta et 
al., 2002, 2006; 
Restucci et al., 
2002; Coomer, 
2008; Michishita et 
al., 2013; Scharf et 
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hemangiopericytoma xenografts 
in mice. 
al., 2013) 
Lewisy (BR96) 
Breast and lung 
carcinomas 
33% of dog tumour samples 
tested express Ley (several 
carcinomas) 
Partial response in 25% 
of dogs tested. Stable 
disease in 33%. Dogs 
negative for Ley had 
progressive disease. 
75% cases had 
anti-mAb reactions  
not preventable by 
immunosupression. 
Anti-mAb 
reactions curtailed 
clinical benefits 
(Friedman et al., 
1993; Henry et al., 
2005) 
 
HER2/neu 
(trastuzumab) 
Breast cancer 
overexpressing 
HER2/neu 
Dog tumours expressing 
HER2/neu have been identified, 
but prognostic value is uncertain. 
Canine and human receptors are 
similar; dogs have a similar 
antigenic phenotype to humans. 
Prognostic value and tumour 
behaviour are more similar to 
humans in cats 
Human monoclonal 
antibodies are able to 
bind dog antigens. 
In cats no 
adaptation is 
possible from 
trastuzumab, since 
human and feline 
receptors differ at 
the EC* region 
(Mottolese et al., 
1994; Demaria et 
al., 2005; Valabrega 
et al., 2007; Gama 
et al., 2008; Gianni 
et al., 2010; Singer 
et al., 
2012)(Cannon, 
2015) 
 
CEA* 
Tumours of colon; 
other epitelial 
tumours 
CEA ligand and receptor aa* are 
99% conserved in dogs compared 
to humans. 
CEA receptor is 
expressed in canine 
mammary carcinoma 
cell lines 
The CEA ligand is 
not differentially 
expressed in 
cancer in dogs 
(Watine et al., 2001; 
Sturgeon et al., 
2008; 
Weichselbaumer et 
al., 2011; Campos et 
al., 2012; Grunnet 
and Sorensen, 2012) 
 
EGFR 
(cetuximab) 
Colorectal; head 
and neck cancer 
In canine mammary tumours, 
EGFR has been associated with 
malignancy and poor prognosis. 
Human and canine receptors are 
similar in the epitopes for 
cetuximab. A caninised version of 
Cetuximab was developed 
Cetuximab is 
tumoristatic to canine 
mammary carcinoma 
cell lines. 
Caninised cetuximab 
(can225IgG) 
maintained function 
Cetuximab is a 
human chimeric 
antibody. 
Caninised version 
is in trial phase. 
(Gama et al., 2009; 
Shiomitsu et al., 
2009; Selvarajah et 
al., 2012; Singer et 
al., 2012, 2014; 
Terragni et al., 
2014; Acharya et 
al., 2015; Queiroga 
et al., 2015) 
Human 
leucocyte 
antigen-DR 
[MHC II] 
(Murine 
version: L243; 
humanised: 
IMMU-114) 
Lymphoma 
L243 and IMMU-114 bind 
human lymphocytes and 
malignant cells in nodal tissue 
Transient disease 
stabilisation. 
Murine led to fever, 
vomiting and short 
mAb half-life. 
Humanised had 
lymphocytopenia and 
half-life of 2h 
Author 
recommended the 
canine 
chimerisation of 
mAb 
(Stein et al., 2011) 
Prostatic 
tumour 
antigens 
Prostate cancer 
and human colon 
Met5 binds to the EC region of 
human and canine Met; dog 
prostate express PSMA mRNA 
Met5 binds to canine 
prostate cancer 
metastatic cell line 
None described 
(Anidjar et al., 
2001; Ross et al., 
2003; Hay et al., 
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 912	
aaa = aminoacids; CEA = carcinoembryonic antigen; EC = extracellular; EGFR = epidermal 913	
growth factor receptor; PSMA = prostate specific membrane antigen; VCAA = vincristine, 914	
cyclophosphamide, L-asparaginase and doxorubicin; VEGF/R = Vascular endothelial growth 915	
factor/receptor;  916	
  917	
(Met5; PSM-
P12; CC49) 
cancer and 50% of cancers have the 
antigen (but not benign tissue) 
GN4; PSM-P12 binds 
to a prostate cell line 
(DPC-1); CC49 was 
successful in imaging 
canine metastases 
2005; Lewis et al., 
2005; Lai et al., 
2008) 
 
PD-1 
Several tumour 
types 
Several canine tumours express 
PD-1, and some also express its 
ligand. Intra-tumoural 
lymphocytes in canine melanoma 
also express PD-1. Anti-PD-1 
increases IFNγ production 
PD-1 being researched 
by Nexvet/Zenoaq 
None described 
(Maekawa et al., 
2014, 2016; Nexvet, 
2016) 
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Table 3 918	
Hurdles and opportunities in monoclonal antibody therapies in veterinary medicine.  919	
 920	
Hurdles Opportunities 
Immunogenicity of human and mouse mAbs in dogs Caninised and chimeric mAbs 
Cost of production of conventional mAbs, with 
cumulative doses 
Alternative mAb production systems and the use of non-
speciated single-dose mAbs. Possible expression systems: 
Insect and yeast cells, transgenic plants and animals. 
Bacterial production of scFv 
Difficult tumour penetration 
In vivo production of the antibody by the host, through viral 
transduction or direct DNA injection; use of scFv antibody 
fragments 
Weak results in vivo following promising results in mice Use of naturally occurring cancers in animals as models to 
study the therapies 
 921	
 922	
  923	
35 
	
Figure legends 924	
 925	
36 
	
Fig. 1. History of monoclonal antibodies and its clinical uses. The top horizontal line presents 926	
the main technological breakthroughs and the year in which they occurred (or the year around 927	
which significant research was done on that subject). The parallel lower lines represent the 928	
mAbs used clinically categorised by their structural classes with regard to humanisation. The 929	
mAbs cited represent a milestone in the use of the technology; other dates of interest are also 930	
shown. RA = rheumatoid arthritis; References: Carter et al., 2001; Lobato and Rabbitts, 2001; 931	
Fong and Small, 2008; Reichert, 2012; Kellerman and Green, 2002; Enever et al., 2009. 932	
 933	
Fig. 2. The most common methods of antibody production and the resulting classes of 934	
antibodies (Jakobovits et al., 2007). 935	
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 936	
Fig. 3. Representation of different formats of the antibody molecule. (a) Full length 937	
monoclonal antibody showing heavy as well as light chain comprised of variable and 938	
constant regions, also the hinge region and the Fc portion which interacts with cell surface 939	
receptors; (b) Fab  molecule which contains no Fc portion of the antibody, thus containing 940	
variable as well as constant regions from heavy and light chains; and (c) scFv which contains 941	
only variable domains of the heavy and light chains for antigen binding. 942	
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 943	
Fig. 4.  Techniques for producing antibodies of different speciation levels. Antibodies can be 944	
derived either from: 1) mice or other laboratory animals immunized with the antigen of 945	
39 
	
interest; unless the mouse was altered genetically to express the immune system from another 946	
species (such as the XenoMouse), antibodies derived from laboratory species will be at most 947	
‘speciated’ (humanized, for instance); 2) directly from the species of interest, in which case 948	
phage display can be used to select the antibody of interest from the vast repertoire available 949	
in any animal. In this case, the antibodies that are derived are ‘humanized’, or ‘caninised’, 950	
etc. 951	
 952	
Fig. 5. The idiotype cascade. The mAb itself is an antigen, and the patient receiving it will 953	
raise an immune response against all the foreign parts of the mAb. Ab2 are created by the 954	
host as a response against the antigen-binding region of the mAb (Ab1). Ab3 is then raised 955	
recognizing the antigen-binding region of Ab2. Therefore, the antigen-binding region of Ab3 956	
is identical to that of the therapeutic mAb (Ab1). 957	
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